identify those suitable for platinum-based doublet chemotherapy, and therefore do not need to be considered. Table 6: List of resources to be considered in the economic analysis Number of Disaggregated unit cost units of resource Setting in Proportion per relevant Provider of which of patients Other Private time Safety Total resource resource is receiving MBS govt health Patient horizon per nets* cost provided resource budget insurer patient receiving resource Resources provided in association with the proposed medical service to deliver the proposed intervention (from Step 1, e.g., co-administered interventions). Identify variations where these may vary across different decision options Test and intervention: EGFR testing and first line afatinib treatment for patients who are EGFR mutation positive and first line platinum doublet chemotherapy for patients who are EGFR mutation wild type EGFR testing costs Re-biopsy (if inadequate Respiratory Hospital 1 unit Estimate tumour sample) physician or of surgeon patients eligible for EGFR testing) Specimen collection MBS Collection To be To be including Patient Episode centre provided in provided in Initiation (PEI) fee submission submission Specimen referred fee MBS Pathology To be To be 10.30 (P11) Lab provided in provided in submission submission Perform EGFR testing Molecular Laboratory 1 unit (100% Proposed 300.00 400.00 pathologist of patients frequency of (75%) eligible for testing 340.00 EGFR (85%) testing) If EGFR mutation positive, patient is eligible for first line treatment with afatinib Consultation for initiation Medical Private 1 unit/EGFR of afatinib (oral tablet) oncologist rooms or mutation data for inpatient/ positive proportion of outpatient patient first line clinic patients EGFR mutation positive Estimate from Lux Lung 3 trial Cost of afatinib (PBS Proposed Community 1 Weighted cost ) PBS item pharmacy cost per dose and for mutation duration of positive treatment patient from Lux Lung 3 trial Follow up consultation Medical Private 1 unit/2 Estimate monitoring disease and oncologist rooms or from Lux treatment (MBS item) inpatient/ R mutation Lung 3 trial outpatient positive clinic patient If EGFR wild type, patient is eligible for first line treatment with platinum doublet chemotherapy Consultation for initiation Medical Private 1 unit / 72.65 of chemotherapy (MBS oncologist rooms or EGFR WT data for
identify those suitable for platinum-based doublet chemotherapy, and therefore do not need to be considered. Table 6: List of resources to be considered in the economic analysis Provider of resource Setting in which resource is provided Proportion of patients receiving resource Number of units of resource per relevant time horizon per patient receiving resource Disaggregated unit cost MBS Safety nets* Other govt budget Private health insurer Patient Total cost Resources provided in association with the proposed medical service to deliver the proposed intervention (from Step 1, e.g., co-administered interventions). Identify variations where these may vary across different decision options Test and intervention: EGFR testing and first line afatinib treatment for patients who are EGFR mutation positive and first line platinum doublet chemotherapy for patients who are EGFR mutation wild type EGFR testing costs Re-biopsy (if inadequate tumour sample) Respiratory physician or surgeon Hospital 1 unit of patients eligible for EGFR testing) Estimate Specimen collection including Patient Episode Initiation (PEI) fee MBS Collection centre To be provided in submission To be provided in submission Specimen referred fee (P11) MBS Pathology Lab To be provided in submission To be provided in submission 10.30 Perform EGFR testing Molecular pathologist Laboratory 1 unit (100% of patients eligible for EGFR testing) Proposed frequency of testing 300.00 (75%) 340.00 (85%) 400.00 If EGFR mutation positive, patient is eligible for first line treatment with afatinib Consultation for initiation of afatinib (oral tablet) Medical oncologist Private rooms or inpatient/ outpatient clinic 1 unit/EGFR mutation positive patient data for proportion of first line patients EGFR mutation positive Estimate from Lux Lung 3 trial Cost of afatinib (PBS cost ) Proposed PBS item Community pharmacy 1 mutation positive patient Weighted cost per dose and for duration of treatment from Lux Lung 3 trial Follow up consultation monitoring disease and treatment (MBS item) Medical oncologist Private rooms or inpatient/ outpatient clinic 1 unit/2 mutation positive patient Estimate from Lux Lung 3 trial If EGFR wild type, patient is eligible for first line treatment with platinum doublet chemotherapy Consultation for initiation of chemotherapy (MBS Medical oncologist Private rooms or 1 unit / EGFR WT data for 72.65 R
1293-EGFR-FinalDAP-Accessible.docx